SK Plasma announced on the 5th that it has signed a technology transfer and license agreement worth a total of EUR 65 million with Proturk, a joint venture established with the Turkish Red Crescent. After tax deductions, the contract amount is approximately KRW 110 billion, the largest single contract since SK Plasma was founded in 2015.

Under this agreement, SK Plasma will grant a license and transfer R&D and production-related technologies so that plasma-derived medicinal products can be manufactured at production facilities to be built in Türkiye.

The technology transfer will proceed by gradually transferring the manufacturing, production, and quality control systems accumulated through the establishment and operation of the Andong plant, and the procedures will be standardized based on a “technology transfer manual.”

Once the production facility with an annual capacity of 600,000 liters is completed in the Cubuk area of Ankara, Türkiye will be able to locally supply essential medicines such as albumin and immunoglobulin, which currently rely 100% on imports. The contract period is nine years, and in addition to technology royalties, SK Plasma will acquire a 15% stake in Proturk for EUR 150,000, enabling it to receive dividend income.

Proturk is a joint venture established in November last year by SK Plasma and the Turkish Red Crescent for the construction of a plasma-derived medicinal product production plant.

Kim Seung-joo, CEO of SK Plasma, said, “This solution goes beyond the export of specific core technologies and represents a model that transfers SK Plasma’s overall operating system to the local site,” adding, “It will become a key platform for the future self-sufficiency solution business model.”

Meanwhile, based on its know-how in building production facilities for plasma-derived medicinal products and system technologies accumulated through the establishment and operation of the Andong plant, SK Plasma is pursuing a global business model of constructing local plants and transferring technology to countries that need to secure self-sufficiency in essential medicines. Having demonstrated its capabilities through project wins in Indonesia and Türkiye, the company plans to expand target countries worldwide and establish its essential medicines solution-sharing model as a new pillar of K-bio.

Popular News